https://pharminent.com/aquipta-recommended-by-nice-for-acute-migraine-treatment/ 2026-06-10T15:25:19Z Pharminent en Aquipta recommended by NICE for acute migraine treatment 2026-06-10T13:35:05Z Blog https://pharminent.com/astrazenecas-extensive-obesity-drug-push-125m-for-ultrasound-aided-genetic-medicine/ 2026-06-10T15:25:22Z Pharminent en AstraZeneca's 'extensive' obesity drug push; $125M for ultrasound-aided genetic medicine 2026-06-10T13:12:00Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-june-9-2026/ 2026-06-10T13:06:02Z Pharminent en Oncology Intelligence Digest • June 9, 2026 2026-06-10T13:05:59Z Blog https://pharminent.com/lilly-wins-new-fda-approval-for-eczema-drug-ebglyss/ 2026-06-10T15:25:24Z Pharminent en Lilly wins new FDA approval for eczema drug Ebglyss 2026-06-10T12:59:56Z Blog https://pharminent.com/discs-fda-meeting-sets-clear-path-for-embattled-rare-blood-disease-drug/ 2026-06-10T15:25:26Z Pharminent en Disc's FDA meeting sets 'clear path' for embattled rare blood disease drug 2026-06-10T12:31:25Z Blog https://pharminent.com/bayers-asundexian-starts-eu-review-for-ischaemic-stroke/ 2026-06-10T15:25:27Z Pharminent en Bayer's asundexian starts EU review for ischaemic stroke 2026-06-10T12:00:43Z Blog https://pharminent.com/abbvies-migraine-drug-cleared-for-migraine-attacks-on-nhs/ 2026-06-10T15:25:29Z Pharminent en AbbVie's migraine drug cleared for migraine attacks on NHS 2026-06-10T10:51:09Z Blog https://pharminent.com/aditxt-and-ignite-announce-merger-plans-with-strategic-partner-2/ 2026-06-10T15:25:30Z Pharminent en Aditxt and Ignite announce merger plans with strategic partner 2026-06-10T10:09:36Z Blog https://pharminent.com/cancer-biotech-parabilis-books-record-ipo-raising-670m/ 2026-06-10T15:25:31Z Pharminent en Cancer biotech Parabilis books record IPO, raising $670m 2026-06-10T09:55:07Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-9-2026/ 2026-06-09T19:57:52Z Pharminent en Strategic News Watch • June 9, 2026 2026-06-09T19:57:50Z Blog https://pharminent.com/alzecure-enters-collaboration-and-with-lilly-for-alzheimers-project/ 2026-06-09T15:55:45Z Pharminent en Alzecure enters collaboration and with Lilly for Alzheimer's project 2026-06-09T13:55:17Z Blog https://pharminent.com/ada-astrazeneca-hands-structure-a-win-with-relatively-underwhelming-glp-1-pill-data/ 2026-06-09T15:55:48Z Pharminent en ADA: AstraZeneca hands Structure a win with 'relatively underwhelming' GLP-1 pill data 2026-06-09T12:41:15Z Blog https://pharminent.com/gsk-pays-10-6b-for-cancer-biotech-nuvalent-in-industrys-second-biggest-buy-of-the-year/ 2026-06-09T15:55:51Z Pharminent en GSK pays $10.6B for cancer biotech Nuvalent in industry's second-biggest buy of the year 2026-06-09T12:12:19Z Blog https://pharminent.com/ada-lilly-bests-novo-again-takes-glp-1-pill-foundayo-to-fda-for-diabetes-approval/ 2026-06-09T15:55:51Z Pharminent en ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval 2026-06-09T11:58:36Z Blog https://pharminent.com/pfizers-hympavzi-secures-fda-expanded-indications-for-haemophilia-2/ 2026-06-09T15:55:53Z Pharminent en Pfizer's Hympavzi secures FDA expanded indications for haemophilia 2026-06-09T09:05:26Z Blog https://pharminent.com/81607-2/ 2026-06-08T23:11:53Z Pharminent en 2026-06-08T23:07:47Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-june-8-2026/ 2026-06-08T20:56:47Z Pharminent en Rare Disease & Gene Therapy Digest • June 8, 2026 2026-06-08T20:56:45Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-8-2026/ 2026-06-08T20:25:31Z Pharminent en Strategic News Watch • June 8, 2026 2026-06-08T20:25:29Z Blog https://pharminent.com/jj-to-acquire-firefly-maker-of-degrader-antibody-drugs-for-up-to-1b/ 2026-06-08T16:06:22Z Pharminent en J&J to acquire Firefly, maker of 'degrader' antibody drugs, for up to $1B 2026-06-08T15:26:00Z Blog https://pharminent.com/ada-26-lillys-dominance-pfizers-foundational-drug-and-roches-me-too-option/ 2026-06-08T16:06:27Z Pharminent en ADA '26: Lilly's dominance, Pfizer's 'foundational' drug and Roche's 'me-too' option 2026-06-08T15:01:00Z Blog https://pharminent.com/ada-boehringer-leans-on-fat-mass-benefits-as-obesity-bet-delivers-less-competitive-weight-reduction/ 2026-06-08T16:06:31Z Pharminent en ADA: Boehringer leans on fat mass benefits as obesity bet delivers 'less competitive' weight reduction 2026-06-08T12:55:54Z Blog https://pharminent.com/incyte-gobbles-up-stars-vega-haematology-unit-in-2bn-deal/ 2026-06-08T16:06:32Z Pharminent en Incyte gobbles up Star's Vega haematology unit in $2bn deal 2026-06-08T12:36:20Z Blog https://pharminent.com/roche-doubles-down-on-btk-with-2-3bn-nurix-deal/ 2026-06-08T16:09:37Z Pharminent en Roche doubles down on BTK with $2.3bn Nurix deal 2026-06-08T10:03:25Z Blog https://pharminent.com/81558-2/ 2026-06-08T00:46:42Z Pharminent en 2026-06-08T00:46:35Z Blog